KEGG   DRUG: Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide
Entry
D10755            Mixture   Drug                                   
Name
Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide;
Genvoya (TN)
Product
GENVOYA (Gilead Sciences), GENVOYA (REMEDYREPACK)
Component
Elvitegravir [DR:D06677], Cobicistat [DR:D09881], Emtricitabine [DR:D01199], (Tenofovir alafenamide fumarate [DR:D10605] | Tenofovir alafenamide [DR:D10428])
Class
Antiviral
 DG03107  Anti-HIV agent
Metabolizing enzyme substrate
 DG01644  CYP2D6 substrate
 DG01633  CYP3A/CYP3A4 substrate
Metabolizing enzyme inhibitor
 DG01645  CYP2D6 inhibitor
 DG02852  CYP3A/CYP3A4 inhibitor
Transporter substrate
 DG01665  ABCB1 substrate
 DG02854  SLC22A2 substrate
 DG03001  CTSA substrate
Transporter inhibitor
 DG01622  ABCB1 inhibitor
Remark
Therapeutic category: 6250
ATC code: J05AR18
Product: D10755<JP/US>
Efficacy
Antiviral
  Disease
HIV-1 infection [DS:H01563]
Comment
Elvitegravir is metabolized by CYP3A.
Cobicistat is metabolized by CYP3A and CYP2D6 and inhibits CYP3A and CYP2D6. It is also a substrate of OCT2 and inhibits P-gp.
Tenofovir alafenamide is a substrate of cathepsin A, CYP3A and P-gp.
Target
HIV-1 reverse transcriptase [KO:K24802]
HIV-1 integrase [KO:K24803]
  Pathway
ko03230  Viral genome structure
ko03240  Viral replication
ko03250  Viral life cycle - HIV-1
Metabolism
Enzyme: CYP3A [HSA:1576 1577 1551], CYP2D6 [HSA:1565], CTSA [HSA:5476]
Transporter: ABCB1 [HSA:5243], SLC22A2 [HSA:6582]
Interaction
CYP inhibition: CYP3A [HSA:1576 1577 1551], CYP2D6 [HSA:1565]
Transporter inhibition: ABCB1 [HSA:5243]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AR Antivirals for treatment of HIV infections, combinations
     J05AR18 Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat
      D10755  Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide <JP/US>
USP drug classification [BR:br08302]
 Antivirals
  Anti-HIV Combinations
   Cobicistat/ Elvitegravir/ Emtricitabine/ Tenofovir Alafenamide
    D10755  Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D10755  Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide
Drug groups [BR:br08330]
 Antiviral
  DG03107  Anti-HIV agent
   D10755  Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide
 Metabolizing enzyme substrate
  DG01644  CYP2D6 substrate
   D10755  Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide
  DG01633  CYP3A/CYP3A4 substrate
   D10755  Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide
 Metabolizing enzyme inhibitor
  DG01645  CYP2D6 inhibitor
   D10755  Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide
  DG02852  CYP3A/CYP3A4 inhibitor
   D10755  Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide
 Transporter substrate
  DG01665  ABCB1 substrate
   D10755  Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide
  DG02854  SLC22A2 substrate
   D10755  Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide
  DG03001  CTSA substrate
   D10755  Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide
 Transporter inhibitor
  DG01622  ABCB1 inhibitor
   D10755  Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide
Drug classes [BR:br08332]
 Antiviral
  DG03107  Anti-HIV agent
   D10755  Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide
Antimicrobials [BR:br08307]
 Antivirals
  Genome replication inhibitor
   HIV integrase inhibitor
    D10755  Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10755
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10755
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10755
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10755
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D10755
 Drug transporters
  D10755
Other DBs
PubChem: 273220351
ChEBI: 90922
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system